DailyMed Label: BORTEZOMIB

DailyMed Label: BORTEZOMIB

2024

DailyMed Prescription

BORTEZOMIB

bortezomib

Bamboo US Bidco LCC

NDC: 83703-532

NDC: 83703-532

Bortezomib for Injection, a proteasome inhibitor, contains bortezomib which is an antineoplastic agent. Bortezomib is a modified dipeptidyl boronic acid. The chemical name for bortezomib, the monomeric boronic acid, is [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid. Bortezomib has the following chemical structure: The molecular weight is 384.24. The molecular formula is C 19 H 25 BN 4 O 4 . The solubility of bortezomib, as the monomeric boronic acid, in water is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5. Bortezomib for Injection is available for intravenous injection or subcutaneous use. Each single-dose vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. It also contains the inactive ingredient: 35 mg mannitol, USP. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine. Bortezomib Chemical Structure

Bortezomib for Injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma. Bortezomib for Injection is indicated for the treatment of adult patients with mantle cell lymphoma.

For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. ( 2.1 , 2.10 ) The recommended starting dose of Bortezomib for Injection is 1.3 mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. ( 2.2 , 2.4 , 2.6 ) Retreatment for Multiple Myeloma: May retreat starting at the last tolerated dose. ( 2.6 ) Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment. ( 2.8 ) Dose must be individualized to prevent overdose. ( 2.10 ) Bortezomib for Injection is for intravenous or subcutaneous use only. Do not administer Bortezomib for Injection by any other route. Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered. The recommended starting dose of Bortezomib for Injection is 1.3 mg/m 2 . Bortezomib for Injection is administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL [see Dosage and Administration (2.10) ]. Bortezomib for Injection retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with Bortezomib for Injection and who have relapsed at least six months after completing prior Bortezomib for Injection treatment. Treatment may be started at the last tolerated dose [see Dosage and Administration (2.6) ] . When administered intravenously, administer Bortezomib for Injection as a 3 to 5 second bolus intravenous injection. Bortezomib for Injection is administered in combination with oral melphalan and oral prednisone for 9, six week treatment cycles as shown in Table 1 . In Cycles 1 to 4, Bortezomib for Injection is administered twice weekly (Days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5 to 9, Bortezomib for Injection is administered once weekly (Days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Bortezomib for Injection. Table 1: Dosage Regimen for Patients with Previously Untreated Multiple Myeloma Twice Weekly Bortezomib for Injection (Cycles 1 to 4) Week 1 2 3 4 5 6 Bortezomib for Injection (1.3 mg/m 2 ) Day 1 -‑ -‑ Day 4 Day 8 Day 11   rest   period Day 22 Day 25 Day 29 Day 32   rest   period Melphalan (9 mg/m 2 ) Prednisone (60 mg/m 2 ) Day 1 Day 2 Day 3 Day 4 -‑ -‑   rest   period -‑ -‑ -‑ -‑   rest   period Once Weekly Bortezomib for Injection (Cycles 5 to 9 when used in combination with Melphalan and Prednisone) Week 1 2 3 4 5 6 Bortezomib for Injection (1.3 mg/m 2 ) Day 1 -‑ -‑ Day 8   rest   period Day 22 Day 29   rest   period Melphalan (9 mg/m 2 ) Prednisone (60 mg/m 2 ) Day 1 Day 2 Day 3 Day 4 -‑ -‑   rest   period -‑ -‑ -‑ -‑   rest   period Prior to initiating any cycle of therapy with Bortezomib for Injection in combination with melphalan and prednisone: Platelet count should be at least 70 x 10 9 /L and the absolute neutrophil count (ANC) should be at least 1 x 10 9 /L Nonhematological toxicities should have resolved to Grade 1 or baseline Table 2: Dose Modifications During Cycles of Combination Bortezomib for Injection, Melphalan and Prednisone Therapy Toxicity Dose Modification or Delay Hematological toxicity during a cycle: If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia withbleeding is observed in the previous cycle Consider reduction of the melphalan dose by 25% in the next cycle If platelet count is not above 30 × 10 9 /L or ANC is not above 0.75 × 10 9 /L on a Bortezomib for Injection dosing day (other than Day 1) Withhold Bortezomib for Injection dose If several Bortezomib for Injection doses in consecutive cycles are withheld due to toxicity Reduce Bortezomib for Injection dose by one dose level (from 1.3 mg/m 2 to 1 mg/m 2 , or from 1 mg/m 2 to 0.7 mg/m 2 ) Grade 3 or higher nonhematological toxicities Withhold Bortezomib for Injection therapy until symptoms of toxicity have resolved to Grade 1 or baseline. Then, Bortezomib for Injection may be reinitiated with one dose level reduction (from 1.3 mg/m 2 to 1 mg/m 2 , or from 1 mg/m 2 to 0.7 mg/m 2 ). For Bortezomib for Injection-related neuropathic pain and/or peripheral neuropathy, hold or modify Bortezomib for Injection as outlined in Table 5 . For information concerning melphalan and prednisone, see manufacturer's prescribing information. Dose modifications guidelines for peripheral neuropathy are provided [see Dosage and Administration (2.7 )] . Bortezomib for Injection (1.3 mg/m2) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for 6, three week treatment cycles as shown in Table 3 . Bortezomib for Injection is administered first followed by rituximab. Bortezomib for Injection is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a ten day rest period on Days 12 to 21. For patients with a response first documented at Cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of Bortezomib for Injection. Table 3: Dosage Regimen for Patients with Previously Untreated Mantle Cell Lymphoma Twice Weekly Bortezomib for Injection (6, Three Week Cycles) Dosing may continue for two more cycles (for a total of eight cycles) if response is first seen at Cycle 6. Week 1 2 3   Bortezomib for Injection (1.3 mg/m 2 ) Day 1 -‑ -‑ Day 4 -‑ Day 8 Day 11   rest   period   Rituximab (375 mg/m 2 )   Cyclophosphamide (750 mg/m 2 )   Doxorubicin (50 mg/m 2 ) Day 1 -‑ -‑ -‑ -‑   rest   period   Prednisone (100 mg/m 2 ) Day 1 Day 2 Day 3 Day 4 Day 5 -‑ -‑   rest   period Prior to the first day of each cycle (other than Cycle 1): Platelet count should be at least 100 x 10 9 /L and absolute neutrophil count (ANC) should be at least 1.5 x 10 9 /L Hemoglobin should be at least 8 g/dL (at least 4.96 mmol/L) Nonhematologic toxicity should have recovered to Grade 1 or baseline Interrupt Bortezomib for Injection treatment at the onset of any Grade 3 hematologic or nonhematological toxicities, excluding neuropathy [see Table 5 , Warnings and Precautions (5 )] . For dose adjustments, see Table 4 below. Table 4: Dose Modifications on Days 4, 8, and 11 During Cycles of Combination Bortezomib for Injection, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone Therapy Toxicity Dose Modification or Delay Hematological Toxicity Grade 3 or higher neutropenia, or a platelet count not at or above 25 × 10 9 /L Withhold Bortezomib for Injection therapy for up to 2 weeks until the patient has an ANC at or above 0.75 × 10 9 /L and a platelet count at or above 25 × 10 9 /L. If, after Bortezomib for Injection has been withheld, the toxicity does not resolve, discontinue Bortezomib for Injection. If toxicity resolves such that the patient has an ANC at or above 0.75 × 10 9 /L and a platelet count at or above 25 x 10 9 /L, Bortezomib for Injection dose should be reduced by 1 dose level (from 1.3 mg/m 2 to 1 mg/m 2 , or from 1 mg/m 2 to 0.7 mg/m 2 )) Grade 3 or higher nonhematological toxicities Withhold Bortezomib for Injection therapy until symptoms of the toxicity have resolved to Grade 2 or better. Then, Bortezomib for Injection may be reinitiated with one dose level reduction (from 1.3 mg/m 2 to 1 mg/m 2 , or from 1 mg/m 2 to 0.7 mg/m 2 ). For Bortezomib for Injection-related neuropathic pain and/or peripheral neuropathy, hold or modify Bortezomib for Injection as outlined in Table 5 . For information concerning rituximab, cyclophosphamide, doxorubicin and prednisone, see manufacturer's prescribing information. Bortezomib for Injection (1.3 mg/m 2 /dose) is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a ten day rest period (Days 12 to 21). For extended therapy of more than eight cycles, Bortezomib for Injection may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for four weeks (Days 1, 8, 15, and 22) followed by a 13 day rest period (Days 23 to 35) [see Clinical Studies (14 )] . At least 72 hours should elapse between consecutive doses of Bortezomib for Injection. Patients with multiple myeloma who have previously responded to treatment with Bortezomib for Injection (either alone or in combination) and who have relapsed at least six months after their prior Bortezomib for Injection therapy may be started on Bortezomib for Injection at the last tolerated dose. Retreated patients are administered Bortezomib for Injection twice weekly (Days 1, 4, 8, and 11) every three weeks for a maximum of eight cycles. At least 72 hours should elapse between consecutive doses of Bortezomib for Injection. Bortezomib for Injection may be administered either as a single agent or in combination with dexamethasone [see Clinical Studies (14.1 )] . Bortezomib for Injection therapy should be withheld at the onset of any Grade 3 nonhematological or Grade 4 hematological toxicities excluding neuropathy as discussed below [see Warnings and Precautions (5) ] . Once the symptoms of the toxicity have resolved, Bortezomib for Injection therapy may be reinitiated at a 25% reduced dose (1.3 mg/m 2 /dose reduced to 1 mg/m 2 /dose; 1 mg/m 2 /dose reduced to 0.7 mg/m 2 /dose). For dose modifications guidelines for peripheral neuropathy, see section 2.7 . Starting Bortezomib for Injection subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients with pre-existing severe neuropathy should be treated with Bortezomib for Injection only after careful risk-benefit assessment. Patients experiencing new or worsening peripheral neuropathy during Bortezomib for Injection therapy may require a decrease in the dose and/or a less dose-intense schedule. For dose or schedule modification guidelines for patients who experience Bortezomib for Injection-related neuropathic pain and/or peripheral neuropathy, see Table 5 . Table 5: Recommended Dose Modification for Bortezomib for Injection - Related Neuropathic Pain and/or Peripheral Sensory or Motor Neuropathy Severity of Peripheral Neuropathy Signs and Symptoms Grading based on NCI Common Terminology Criteria CTCAE v4.0 Modification of Dose and Regimen Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) without pain or loss of function No action Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental Activities of Daily Living (ADL) Instrumental ADL: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money, etc. ) Reduce Bortezomib for Injection to 1 mg/m 2 Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADL Self care ADL: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden ) Withhold Bortezomib for Injection therapy until toxicity resolves. When toxicity resolves reinitiate with a reduced dose of Bortezomib for Injection at 0.7 mg/m 2 once per week. Grade 4 (life-threatening consequences; urgent intervention indicated) Discontinue Bortezomib for Injection Do not adjust the starting dose for patients with mild hepatic impairment. Start patients with moderate or severe hepatic impairment at a reduced dose of 0.7 mg/m 2 per injection during the first cycle, and consider subsequent dose escalation to 1 mg/m 2 or further dose reduction to 0.5 mg/m 2 based on patient tolerance (see Table 6 ) [see Use in Specific Populations (8.7 ), Clinical Pharmacology (12.3 )] . Table 6: Recommended Starting Dose Modification for Bortezomib for Injection in Patients with Hepatic Impairment Bilirubin Level SGOT (AST)Levels Modification of Starting Dose   Mild Less than or equal to 1x ULN More than ULN None More than 1x to 1.5x ULN Any None   Moderate More than 1.5x to 3x ULN Any Reduce Bortezomib for Injection to 0.7 mg/m 2 in the first cycle. Consider dose escalation to 1 mg/m 2 or further dose reduction to 0.5 mg/m 2 in subsequent cycles based on patient tolerability.   Severe More than 3x ULN Any Abbreviations: SGOT = serum glutamic oxaloacetic transaminase; AST = aspartate aminotransferase; ULN = upper limit of the normal range. The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent overdose [see Dosage and Administration (2.10 )] . When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated. If local injection site reactions occur following Bortezomib for Injection administration subcutaneously, a less concentrated Bortezomib for Injection solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously [see Dosage and Administration (2.10 )] . Alternatively, consider use of the intravenous route of administration [see Dosage and Administration (2.10 )] . Bortezomib for Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Use proper aseptic technique. Reconstitute only with 0.9% sodium chloride . The reconstituted product should be a clear and colorless solution. Different volumes of 0.9% sodium chloride are used to reconstitute the product for the different routes of administration. The reconstituted concentration of bortezomib for subcutaneous administration (2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous administration (1 mg/mL). Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered [see Dosage and Administration (2.9 )] . For each 3.5 mg single-dose vial of bortezomib, reconstitute with the following volume of 0.9% sodium chloride based on route of administration ( Table 7 ) : Table 7: Reconstitution Volumes and Final Concentration for Intravenous and Subcutaneous Administration Route of Administration Bortezomib (mg/vial) Diluent (0.9% Sodium Chloride) Final Bortezomib Concentration (mg/mL) Intravenous 3.5 mg 3.5 mL 1 mg/mL Subcutaneous 3.5 mg 1.4 mL 2.5 mg/mL Dose must be individualized to prevent overdosage. After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted Bortezomib for Injection to be administered: Intravenous Administration [1 mg/mL concentration]           Bortezomib for Injection dose (mg/m 2 ) x patient BSA (m 2 )     =    Total Bortezomib for Injection volume (mL) to be administered                                                   1 mg/mL Subcutaneous Administration [2.5 mg/mL concentration]           Bortezomib for Injection dose (mg/m 2 ) x patient BSA (m 2 )     =    Total Bortezomib for Injection volume (mL) to be administered                                                   2.5 mg/mL Stickers that indicate the route of administration are provided with each Bortezomib for Injection vial. These stickers should be placed directly on the syringe of Bortezomib for Injection once Bortezomib for Injection is prepared to help alert practitioners of the correct route of administration for Bortezomib for Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If any discoloration or particulate matter is observed, the reconstituted product should not be used. Stability Unopened vials of Bortezomib for Injection are stable until the date indicated on the package when stored in the original package protected from light. Bortezomib for Injection contains no antimicrobial preservative. Administer reconstituted Bortezomib for Injection within eight hours of preparation. When reconstituted as directed, Bortezomib for Injection may be stored at 25ºC (77ºF). The reconstituted material may be stored in the original vial and/or the syringe prior to administration. The product may be stored for up to eight hours in a syringe; however, total storage time for the reconstituted material must not exceed eight hours when exposed to normal indoor lighting. Discard unused portion.

For injection: Each single-dose vial of Bortezomib for Injection contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder for reconstitution and withdrawal of the appropriate individual patient dose [see Dosage and Administration (2.10 )] . For injection: Single-dose vial contains 3.5 mg of bortezomib as lyophilized powder for reconstitution and withdrawal of the appropriate individual patient dose. ( 3 )

Bortezomib for Injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [see Adverse Reactions (6.1 )] . Bortezomib for Injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of Bortezomib for Injection. Patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. ( 4 ) Contraindicated for intrathecal administration. ( 4 )

Peripheral Neuropathy: Manage with dose modification or discontinuation. ( 2.7 ) Patients with pre-existing severe neuropathy should be treated with Bortezomib for Injection only after careful risk-benefit assessment. ( 2.7 , 5.1 ) Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. ( 5.2 ) Cardiac Toxicity: Worsening of and development of cardiac failure has occurred. Closely monitor patients with existing heart disease or risk factors for heart disease. ( 5.3 ) Pulmonary Toxicity: Acute respiratory syndromes have occurred. Monitor closely for new or worsening symptoms and consider interrupting Bortezomib for Injection therapy. ( 5.4 ) Posterior Reversible Encephalopathy Syndrome: Consider MRI imaging for onset of visual or neurological symptoms; discontinue Bortezomib for Injection if suspected. ( 5.5 ) Gastrointestinal Toxicity: Nausea, diarrhea, constipation, and vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement. ( 5.6 ) Thrombocytopenia and Neutropenia: Monitor complete blood counts regularly throughout treatment. ( 5.7 ) Tumor Lysis Syndrome: Closely monitor patients with high tumor burden. ( 5.8 ) Hepatic Toxicity: Monitor hepatic enzymes during treatment. Interrupt Bortezomib for Injection therapy to assess reversibility. ( 5.9 ) Thrombotic Microangiopathy: Monitor for signs and symptoms. Discontinue Bortezomib for Injection if suspected. ( 5.10 ) Embryo-Fetal Toxicity: Bortezomib for Injection can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.11 ) Bortezomib for Injection treatment causes a peripheral neuropathy that is predominantly sensory; however, cases of severe sensory and motor peripheral neuropathy have been reported. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including ≥Grade 3) during treatment with Bortezomib for Injection. Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. In the Phase 3 relapsed multiple myeloma trial comparing Bortezomib for Injection subcutaneous vs intravenous, the incidence of Grade ≥2 peripheral neuropathy was 24% for subcutaneous and 39% for intravenous. Grade ≥3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 15% in the intravenous treatment group [see Adverse Reactions (6.1) ] . Starting Bortezomib for Injection subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients experiencing new or worsening peripheral neuropathy during Bortezomib for Injection therapy may require a decrease in the dose and/or a less dose-intense schedule [see Dosage and Administration (2.7 )] . In the Bortezomib for Injection vs dexamethasone Phase 3 relapsed multiple myeloma study, improvement in or resolution of peripheral neuropathy was reported in 48% of patients with ≥Grade 2 peripheral neuropathy following dose adjustment or interruption. Improvement in or resolution of peripheral neuropathy was reported in 73% of patients who discontinued due to Grade 2 neuropathy or who had ≥Grade 3 peripheral neuropathy in the Phase 2 multiple myeloma studies. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. The incidence of hypotension (postural, orthostatic, and hypotension NOS) was 8% [see Adverse Reactions (6.1) ] . These events are observed throughout therapy. Patients with a history of syncope, patients receiving medications known to be associated with hypotension, and patients who are dehydrated may be at increased risk of hypotension. Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. Acute development or exacerbation of congestive heart failure and new onset of decreased left ventricular ejection fraction have occurred during Bortezomib for Injection therapy, including reports in patients with no risk factors for decreased left ventricular ejection fraction [see Adverse Reactions (6.1) ] . Patients with risk factors for, or existing heart disease should be frequently monitored. In the relapsed multiple myeloma study of Bortezomib for Injection vs dexamethasone, the incidence of any treatment-related cardiac disorder was 8% and 5% in the Bortezomib for Injection and dexamethasone groups, respectively. The incidence of adverse reactions suggestive of heart failure (acute pulmonary edema, pulmonary edema, cardiac failure, congestive cardiac failure, cardiogenic shock) was ≤1% for each individual reaction in the Bortezomib for Injection group. In the dexamethasone group the incidence was ≤1% for cardiac failure and congestive cardiac failure; there were no reported reactions of acute pulmonary edema, pulmonary edema, or cardiogenic shock. There have been isolated cases of QT-interval prolongation in clinical studies; causality has not been established. Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration have occurred in patients receiving Bortezomib for Injection. Some of these events have been fatal. In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and Bortezomib for Injection for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. There have been reports of pulmonary hypertension associated with Bortezomib for Injection administration in the absence of left heart failure or significant pulmonary disease. In the event of new or worsening cardiopulmonary symptoms, consider interrupting Bortezomib for Injection until a prompt and comprehensive diagnostic evaluation is conducted. Posterior Reversible Encephalopathy Syndrome (PRES; formerly termed Reversible Posterior Leukoencephalopathy Syndrome (RPLS)) has occurred in patients receiving Bortezomib for Injection. PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. Brain imaging, preferably MRI (Magnetic Resonance Imaging), is used to confirm the diagnosis. In patients developing PRES, discontinue Bortezomib for Injection. The safety of reinitiating Bortezomib for Injection therapy in patients previously experiencing PRES is not known. Bortezomib for Injection treatment can cause nausea, diarrhea, constipation, and vomiting [see Adverse Reactions (6.1) ] sometimes requiring use of antiemetic and antidiarrheal medications. Ileus can occur. Fluid and electrolyte replacement should be administered to prevent dehydration. Interrupt Bortezomib for Injection for severe symptoms. Bortezomib for Injection is associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in the treatment regimens studied. Monitor complete blood counts (CBC) frequently during treatment with Bortezomib for Injection. Measure platelet counts prior to each dose of Bortezomib for Injection. Adjust dose/schedule for thrombocytopenia [see Dosage and Administration (2.6) ] . Gastrointestinal and intracerebral hemorrhage has occurred during thrombocytopenia in association with Bortezomib for Injection. Support with transfusions and supportive care, according to published guidelines. In the single agent, relapsed multiple myeloma study of Bortezomib for Injection vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in Table 8 . The incidence of bleeding (≥Grade 3) was 2% on the Bortezomib for Injection arm and was <1% in the dexamethasone arm. Table 8: Severity of Thrombocytopenia Related to Pretreatment Platelet Count in the Relapsed Multiple Myeloma Study of Bortezomib for Injection vs Dexamethasone Pretreatment Platelet Count A baseline platelet count of 50,000/µL was required for study eligibility Number of Patients (N=331) Data were missing at baseline for one patient Number (%) of Patients with Platelet Count <10,000/µL Number (%) of Patients with Platelet Count 10,000 to 25,000/µL ≥75,000/µL 309 8 (3%) 36 (12%) ≥50,000/µL to <75,000/µL 14 2 (14%) 11 (79%) ≥10,000/µL to <50,000/µL 7 1 (14%) 5 (71%) In the combination study of Bortezomib for Injection with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12 . The incidence of bleeding events (≥Grade 3) was 1.7% in the VcR-CAP arm (four patients) and was 1.2% in the R-CHOP arm (three patients). Platelet transfusions were given to 23% of the patients in the VcR-CAP arm and 3% of the patients in the R-CHOP arm. The incidence of neutropenia (≥Grade 4) was 70% in the VcR-CAP arm and was 52% in the R-CHOP arm. The incidence of febrile neutropenia (≥Grade 4) was 5% in the VcR-CAP arm and was 6% in the R-CHOP arm. Myeloid growth factor support was provided at a rate of 78% in the VcR-CAP arm and 61% in the R-CHOP arm. Tumor lysis syndrome has been reported with Bortezomib for Injection therapy. Patients at risk of tumor lysis syndrome are those with high tumor burden prior to treatment. Monitor patients closely and take appropriate precautions. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Other reported hepatic reactions include hepatitis, increases in liver enzymes, and hyperbilirubinemia. Interrupt Bortezomib for Injection therapy to assess reversibility. There is limited rechallenge information in these patients. Cases, sometimes fatal, of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported in the postmarketing setting in patients who received Bortezomib for Injection. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop Bortezomib for Injection and evaluate. If the diagnosis of TTP/HUS is excluded, consider restarting Bortezomib for Injection. The safety of reinitiating Bortezomib for Injection therapy in patients previously experiencing TTP/HUS is not known. Based on the mechanism of action and findings in animals, Bortezomib for Injection can cause fetal harm when administered to a pregnant woman. Bortezomib administered to rabbits during organogenesis at a dose approximately 0.5 times the clinical dose of 1.3 mg/m 2 based on body surface area caused postimplantation loss and a decreased number of live fetuses [see Use in Specific Populations (8.1 )] . Advise females of reproductive potential to use effective contraception during treatment with Bortezomib for Injection and for seven months following treatment. Advise males with female partners of reproductive potential to use effective contraception during treatment with Bortezomib for Injection and for four months following treatment. If Bortezomib for Injection is used during pregnancy or if the patient becomes pregnant during Bortezomib for Injection treatment, the patient should be apprised of the potential risk to the fetus [see Use in Specific Populations (8.1 , 8.3 ), Nonclinical Toxicology (13.1 )].

The following clinically significant adverse reactions are also discussed in other sections of the labeling:

Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. ( 7.1 ) Strong CYP3A4 Inducers: Avoid concomitant use. (7.3) Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [see Clinical Pharmacology (12.3 )] which may decrease Bortezomib for Injection efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [see Clinical Pharmacology (12.3 )] which may increase the risk of Bortezomib for Injection toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors. No clinically significant drug interactions have been observed when Bortezomib for Injection was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3 )] .

Patients with diabetes may require close monitoring of blood glucose and adjustment of antidiabetic medication. ( 8.8 ) Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1 )] and findings in animals, Bortezomib for Injection can cause fetal harm when administered to a pregnant woman. There are no studies with the use of Bortezomib for Injection in pregnant women to inform drug-associated risks. Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see Data ) . Advise pregnant women of the potential risk to the fetus. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Bortezomib was not teratogenic in nonclinical developmental toxicity studies in rats and rabbits at the highest dose tested (0.075 mg/kg; 0.5 mg/m 2 in the rat and 0.05 mg/kg; 0.6 mg/m 2 in the rabbit) when administered during organogenesis. These dosages are approximately 0.5 times the clinical dose of 1.3 mg/m 2 based on body surface area. Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (approximately 0.5 times the clinical dose of 1.3 mg/m 2 based on body surface area). Pregnant rabbits given bortezomib during organogenesis at a dose of 0.05 mg/kg (0.6 mg/m 2 ) experienced significant postimplantation loss and decreased number of live fetuses. Live fetuses from these litters also showed significant decreases in fetal weight. Risk Summary There are no data on the presence of bortezomib or its metabolites in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Because many drugs are excreted in human milk and because the potential for serious adverse reactions in a breastfed child from Bortezomib for Injection is unknown, advise nursing women not to breastfeed during treatment with Bortezomib for Injection and for two months after treatment. Based on its mechanism of action and findings in animals, Bortezomib for Injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1 )]. Pregnancy Testing Conduct pregnancy testing in females of reproductive potential prior to initiating Bortezomib for Injection treatment. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with Bortezomib for Injection and for seven months after the last dose. Males Males with female partners of reproductive potential should use effective contraception during treatment with Bortezomib for Injection and for four months after the last dose. Infertility Based on the mechanism of action and findings in animals, Bortezomib for Injection may have an effect on either male or female fertility [see Nonclinical Toxicology (13.1 )] . Safety and effectiveness have not been established in pediatric patients. The activity and safety of Bortezomib for Injection in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies (pre-B cell ALL 77%, 16% with T-cell ALL, and 7% T-cell lymphoblastic lymphoma (LL)), all of whom relapsed within 36 months of initial diagnosis in a single-arm multicenter, nonrandomized cooperative group trial. An effective reinduction multiagent chemotherapy regimen was administered in three blocks. Block 1 included vincristine, prednisone, doxorubicin and pegaspargase; Block 2 included cyclophosphamide, etoposide and methotrexate; Block 3 included high-dose cytosine arabinoside and asparaginase.Bortezomib for Injection was administered at a dose of 1.3 mg/m 2 as a bolus intravenous injection on Days 1, 4, 8, and 11 of Block 1 and Days 1, 4, and 8 of Block 2. There were 140 patients with ALL or LL enrolled and evaluated for safety. The median age was ten years (range: 1 to 26), 57% were male, 70% were white, 14% were black, 4% were Asian, 2% were American Indian/Alaska Native, 1% were Pacific Islander. The activity was evaluated in a prespecified subset of the first 60 evaluable patients enrolled on the study with pre-B ALL ≤21 years and relapsed <36 months from diagnosis. The complete remission (CR) rate at day 36 was compared to that in a historical control set of patients who had received the identical backbone therapy without Bortezomib for Injection. There was no evidence that the addition of Bortezomib for Injection had any impact on the CR rate. No new safety concerns were observed when Bortezomib for Injection was added to a chemotherapy backbone regimen as compared with a historical control group in which the backbone regimen was given without Bortezomib for Injection. The BSA-normalized clearance of bortezomib in pediatric patients was similar to that observed in adults. Of the 669 patients enrolled in the relapsed multiple myeloma study, 245 (37%) were 65 years of age or older: 125 (38%) on the Bortezomib for Injection arm and 120 (36%) on the dexamethasone arm. Median time to progression and median duration of response for patients ≥65 were longer on Bortezomib for Injection compared to dexamethasone [5.5 mo vs 4.3 mo, and 8.0 mo vs 4.9 mo, respectively]. On the Bortezomib for Injection arm, 40% (n=46) of evaluable patients aged ≥65 experienced response (CR + PR) vs 18% (n=21) on the dexamethasone arm. The incidence of Grade 3 and 4 events was 64%, 78% and 75% for Bortezomib for Injection patients ≤50, 51 to 64 and ≥65 years old, respectively [see Adverse Reactions (6.1 ), Clinical Studies (14.1 )] . No overall differences in safety or effectiveness were observed between patients ≥age 65 and younger patients receiving Bortezomib for Injection; but greater sensitivity of some older individuals cannot be ruled out. No starting dosage adjustment of Bortezomib for Injection is recommended for patients with renal impairment. In patients requiring dialysis, Bortezomib for Injection should be administered after the dialysis procedure [see Clinical Pharmacology (12.3 )] . No starting dosage adjustment of Bortezomib for Injection is recommended for patients with mild hepatic impairment (total bilirubin ≤1x ULN and AST >ULN, or total bilirubin >1 to 1.5x ULN and any AST). The exposure of bortezomib is increased in patients with moderate (total bilirubin ≥1.5 to 3x ULN and any AST) and severe (total bilirubin >3x ULN and any AST) hepatic impairment. Reduce the starting dose in patients with moderate or severe hepatic impairment [see Dosage and Administration (2.8 ), Clinical Pharmacology (12.3 )] . During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving Bortezomib for Injection treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.

Bortezomib for Injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder. NDC 10019-991-01 3.5 mg single-dose vial Unopened vials may be stored at controlled room temperature 25ºC (77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Retain in original package to protect from light. Follow guidelines for handling and disposal for hazardous drugs, including the use of gloves and other protective clothing to prevent skin contact 1 .

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro . Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. Following twice weekly administration of 1 mg/m 2 and 1.3 mg/m 2 bortezomib doses, the maximum inhibition of 20S proteasome activity (relative to baseline) in whole blood was observed five minutes after drug administration. Comparable maximum inhibition of 20S proteasome activity was observed between 1 and 1.3 mg/m 2 doses. Maximal inhibition ranged from 70% to 84% and from 73% to 83% for the 1 mg/m 2 and 1.3 mg/m 2 dose regimens, respectively. Following intravenous administration of 1 mg/m 2 and 1.3 mg/m 2 doses, the mean maximum plasma concentrations of bortezomib (C max ) after the first dose (Day 1) were 57 and 112 ng/mL, respectively. When administered twice weekly, the mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1 mg/m 2 dose and 89 to 120 ng/mL for the 1.3 mg/m 2 dose. Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m 2 dose to patients with multiple myeloma, the total systemic exposure after repeat dose administration (AUC last ) was equivalent for subcutaneous and intravenous administration. The AUC last geometric mean ratio (90% confidence interval) was 0.99 (0.80 to 1.23). The C max after subcutaneous administration (20.4 ng/mL) was lower than after intravenous administration (223 ng/mL) with repeat dose administration. Distribution The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/m 2 following single- or repeat-dose administration of 1 mg/m 2 or 1.3 mg/m 2 to patients with multiple myeloma. The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL. Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose. The mean total body clearances were 102 and 112 L/h following the first dose for doses of 1 mg/m 2 and 1.3 mg/m 2 , respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1 and 1.3 mg/m 2 , respectively. Metabolism Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9. Excretion The pathways of elimination of bortezomib have not been characterized in humans. Specific Populations No clinically significant differences in the pharmacokinetics of bortezomib were observed based on age, sex, or renal impairment (including patients administered Bortezomib for Injection after dialysis). The effect of race on bortezomib pharmacokinetics is unknown. Patients with Hepatic Impairment Following administration of bortezomib doses ranging from 0.5 to 1.3 mg/m 2 , mild (total bilirubin ≤1x ULN and AST >ULN, or total bilirubin >1 to 1.5x ULN and any AST) hepatic impairment did not alter dose-normalized bortezomib AUC when compared to patients with normal hepatic function. Dose normalized mean bortezomib AUC increased by approximately 60% in patients with moderate (total bilirubin >1.5 to 3x ULN and any AST) or severe (total bilirubin >3x ULN and any AST) hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment. Drug Interaction Studies Clinical Studies No clinically significant differences in bortezomib pharmacokinetics were observed when coadministered with dexamethasone (weak CYP3A4 inducer), omeprazole (strong CYP2C19 inhibitor), or melphalan in combination with prednisone. Strong CYP3A4 Inhibitor Coadministration with ketoconazole (strong CYP3A4 inhibitor) increased bortezomib exposure by 35%. Strong CYP3A4 Inducer Coadministration with rifampin (strong CYP3A4 inducer) decreased bortezomib exposure by approximately 45%. In Vitro Studies Bortezomib may inhibit CYP2C19 activity and increase exposure to drugs that are substrates for this enzyme.

Carcinogenicity studies have not been conducted with bortezomib. Bortezomib showed clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary cells. Bortezomib was not genotoxic when tested in the in vitro mutagenicity assay (Ames test) and in vivo micronucleus assay in mice. Fertility studies with bortezomib were not performed but evaluation of reproductive tissues has been performed in the general toxicity studies. In the six month rat toxicity study, degenerative effects in the ovary were observed at doses ≥0.3  mg/m 2 (one-fourth of the recommended clinical dose), and degenerative changes in the testes occurred at 1.2  mg/m 2 . Cardiovascular Toxicity Studies in monkeys showed that administration of dosages approximately twice the recommended clinical dose resulted in heart rate elevations, followed by profound progressive hypotension, bradycardia, and death 12 to 14 hours postdose. Doses ≥1.2 mg/m 2 induced dose-proportional changes in cardiac parameters. Bortezomib has been shown to distribute to most tissues in the body, including the myocardium. In a repeated dosing toxicity study in the monkey, myocardial hemorrhage, inflammation, and necrosis were also observed. Chronic Administration In animal studies at a dose and schedule similar to that recommended for patients (twice weekly dosing for two weeks followed by one week rest), toxicities observed included severe anemia and thrombocytopenia, and gastrointestinal, neurological and lymphoid system toxicities. Neurotoxic effects of bortezomib in animal studies included axonal swelling and degeneration in peripheral nerves, dorsal spinal roots, and tracts of the spinal cord. Additionally, multifocal hemorrhage and necrosis in the brain, eye, and heart were observed.

Randomized, Open-Label Clinical Study in Patients with Previously Untreated Multiple Myeloma A prospective, international, randomized (1:1), open-label clinical study (NCT00111319) of 682 patients was conducted to determine whether Bortezomib for Injection administered intravenously (1.3 mg/m 2 ) in combination with melphalan (9 mg/m 2 ) and prednisone (60 mg/m 2 ) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m 2 ) and prednisone (60 mg/m 2 ) in patients with previously untreated multiple myeloma. Treatment was administered for a maximum of nine cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity. Antiviral prophylaxis was recommended for patients on the Bortezomib for Injection study arm. The median age of the patients in the study was 71 years (48;91), 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80 (60;100). Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/L (64;165), and a median platelet count of 221,500/microliter (33,000;587,000). Efficacy results for the trial are presented in Table 14 . At a prespecified interim analysis (with median follow-up of 16.3 months), the combination of Bortezomib for Injection, melphalan and prednisone therapy resulted in significantly superior results for time to progression, progression-free survival, overall survival and response rate. Further enrollment was halted, and patients receiving melphalan and prednisone were offered Bortezomib for Injection in addition. A later, prespecified analysis of overall survival (with median follow-up of 36.7 months with a hazard ratio of 0.65, 95% CI: 0.51, 0.84) resulted in a statistically significant survival benefit for the Bortezomib for Injection, melphalan and prednisone treatment arm despite subsequent therapies including Bortezomib for Injection based regimens. In an updated analysis of overall survival based on 387 deaths (median follow-up 60.1 months), the median overall survival for the Bortezomib for Injection, melphalan and prednisone treatment arm was 56.4 months and for the melphalan and prednisone treatment arm was 43.1 months, with a hazard ratio of 0.695 (95% CI: 0.57, 0.85). Table 14: Summary of Efficacy Analyses in the Previously Untreated Multiple Myeloma Study Efficacy Endpoint Bortezomib for Injection, Melphalan and Prednisone (n=344) Melphalan and Prednisone (n=338) Time to Progression Events n (%) 101 (29) 152 (45) Median Kaplan-Meier estimate (months) (95% CI) 20.7 (17.6, 24.7) 15.0 (14.1, 17.9) Hazard ratio Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: beta 2‑ microglobulin, albumin, and region. A hazard ratio less than one indicates an advantage for Bortezomib for Injection, melphalan and prednisone (95% CI) 0.54 (0.42, 0.70) p-value p-value based on the stratified log-rank test adjusted for stratification factors: beta 2-microglobulin, albumin, and region 0.000002 Progression-Free Survival Events n (%) 135 (39) 190 (56) Median (months) (95% CI) 18.3 (16.6, 21.7) 14.0 (11.1, 15.0) Hazard ratio (95% CI) 0.61 (0.49, 0.76) p-value 0.00001 Response Rate CR EBMT criteria n (%) 102 (30) 12 (4) PR n (%) 136 (40) 103 (30) nCR n (%) 5 (1) 0 CR + PR n (%) 238 (69) 115 (34) p-value p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors <10 -10 Overall Survival at Median Follow-Up of 36.7 Months Events (deaths) n (%) 109 (32) 148 (44) Median (months) (95% CI) Not Reached (46.2, NR) 43.1 (34.8, NR) Hazard ratio (95% CI) 0.65 (0.51, 0.84) p-value 0.00084 Note: All results are based on the analysis performed at a median follow-up duration of 16.3 months except for the overall survival analysis. TTP was statistically significantly longer on the Bortezomib for Injection, melphalan and prednisone arm (see Figure 1 ). (median follow-up 16.3 months) Figure 1: Time to Progression Bortezomib for Injection, Melphalan and Prednisone vs Melphalan and Prednisone Overall survival was statistically significantly longer on the Bortezomib for Injection, melphalan and prednisone arm (see Figure 2 ). (median follow-up 60.1 months) Randomized, Clinical Study in Relapsed Multiple Myeloma of Bortezomib for Injection vs Dexamethasone A prospective Phase 3, international, randomized (1:1), stratified, open-label clinical study (NCT00048230) enrolling 669 patients was designed to determine whether Bortezomib for Injection resulted in improvement in time to progression (TTP) compared to high-dose dexamethasone in patients with progressive multiple myeloma following 1 to 3 prior therapies. Patients considered to be refractory to prior high-dose dexamethasone were excluded as were those with baseline Grade ≥2 peripheral neuropathy or platelet counts <50,000/µL. A total of 627 patients were evaluable for response. Stratification factors were based on the number of lines of prior therapy the patient had previously received (one previous line vs more than one line of therapy), time of progression relative to prior treatment (progression during or within six months of stopping their most recent therapy vs relapse >6 months after receiving their most recent therapy), and screening beta 2 -microglobulin levels (≤2.5 mg/L vs >2.5 mg/L). Baseline patient and disease characteristics are summarized in Table 15 . Table 15: Summary of Baseline Patient and Disease Characteristics in the Relapsed Multiple Myeloma Study Patient Characteristics Bortezomib for Injection (N=333) Dexamethasone (N=336)   Median age in years (range) 62.0 (33, 84) 61.0 (27, 86)   Gender: Male/female 56%/44% 60%/40%   Race: Caucasian/black/other 90%/6%/4% 88%/7%/5%   Karnofsky performance status score ≤70 13% 17%   Hemoglobin <100 g/L 32% 28%   Platelet count <75 x 10 9 /L 6% 4% Disease Characteristics   Type of myeloma (%): IgG/IgA/Light chain 60%/23%/12% 59%/24%/13%   Median beta2-microglobulin (mg/L) 3.7 3.6   Median albumin (g/L) 39.0 39.0   Creatinine clearance ≤30 mL/min [n (%)] 17 (5%) 11 (3%) Median Duration of Multiple Myeloma Since Diagnosis (Years) 3.5 3.1 Number of Prior Therapeutic Lines of Treatment   Median 2 2   1 prior line 40% 35%   >1 prior line 60% 65% Previous Therapy   Any prior steroids, e.g., dexamethasone, VAD 98% 99%   Any prior anthracyclines, e.g., VAD, mitoxantrone 77% 76% 77% 76%   Any prior alkylating agents, e.g., MP, VBMCP 91% 92%   Any prior thalidomide therapy 48% 50%   Vinca alkaloids 74% 72%   Prior stem cell transplant/other high-dose therapy 67% 68%   Prior experimental or other types of therapy 3% 2% Patients in the Bortezomib for Injection treatment group were to receive 8, three week treatment cycles followed by 3, five week treatment cycles of Bortezomib for Injection. Patients achieving a CR were treated for four cycles beyond first evidence of CR. Within each three week treatment cycle, Bortezomib for Injection 1.3 mg/m 2 /dose alone was administered by intravenous bolus twice weekly for two weeks on Days 1, 4, 8, and 11 followed by a ten day rest period (Days 12 to 21). Within each five week treatment cycle, Bortezomib for Injection 1.3 mg/m 2 /dose alone was administered by intravenous bolus once weekly for four weeks on Days 1, 8, 15, and 22 followed by a 13 day rest period (Days 23 to 35) [see Dosage and Administration (2.2 )] . Patients in the dexamethasone treatment group were to receive 4, five week treatment cycles followed by 5, four week treatment cycles. Within each five week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4, 9 to 12, and 17 to 20 followed by a 15 day rest period (Days 21 to 35). Within each four week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4 followed by a 24 day rest period (Days 5 to 28). Patients with documented progressive disease on dexamethasone were offered Bortezomib for Injection at a standard dose and schedule on a companion study. Following a preplanned interim analysis of time to progression, the dexamethasone arm was halted and all patients randomized to dexamethasone were offered Bortezomib for Injection, regardless of disease status. In the Bortezomib for Injection arm, 34% of patients received at least one Bortezomib for Injection dose in all eight of the three week cycles of therapy, and 13% received at least one dose in all 11 cycles. The average number of Bortezomib for Injection doses during the study was 22, with a range of 1 to 44. In the dexamethasone arm, 40% of patients received at least one dose in all four of the five week treatment cycles of therapy, and 6% received at least one dose in all nine cycles. The time to event analyses and response rates from the relapsed multiple myeloma study are presented in Table 16 . Response and progression were assessed using the European Group for Blood and Marrow Transplantation (EBMT) criteria. Complete response (CR) required <5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF - ). Partial response (PR) requires ≥50% reduction in serum myeloma protein and ≥90% reduction of urine myeloma protein on at least two occasions for a minimum of at least six weeks along with stable bone disease and normal calcium. Near complete response (nCR) was defined as meeting all the criteria for complete response including 100% reduction in M-protein by protein electrophoresis; however, M- protein was still detectable by immunofixation (IF + ). Table 16: Summary of Efficacy Analyses in the Relapsed Multiple Myeloma Study Efficacy Endpoint All Patients 1 Prior Line of Therapy >1 Prior Line of Therapy Bortezomib for Injection Dex Bortezomib for Injection Dex Bortezomib for Injection Dex (n=333) (n=336) (n=132) (n=119) (n=200) (n=217) Time to Progression Events n (%) 147 (44) 196 (58) 55 (42) 64 (54) 92 (46) 132 (61) Median Kaplan-Meier estimate (95%CI) 6.2 mo (4.9, 6.9) 3.5 mo (2.9,4.2) 7.0 mo (6.2, 8.8) 5.6 mo (3.4,6.3) 4.9 mo (4.2, 6.3) 2.9 mo (2.8,3.5) Hazard ratio Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than one indicates an advantage for Bortezomib for Injection (95%CI) 0.55 (0.44, 0.69) 0.55 (0.38, 0.81) 0.54 (0.41, 0.72) p-value p-value based on the stratified log-rank test including randomization stratification factors <0.0001 0.0019 <0.0001 Overall Survival Events (deaths) n (%) 51 (15) 84 (25) 12 (9) 24(20) 39 (20) 60 (28) Hazard ratio (95% CI) 0.57 (0.40, 0.81) 0.39 (0.19, 0.81) 0.65 (0.43, 0.97) p-value , Precise p-value cannot be rendered <0.05 <0.05 <0.05 Response Rate Population Response population includes patients who had measurable disease at baseline and received at least one dose of study drug n=627 n=315 n=312 n=128 n=110 n=187 n=202 CR EBMT criteria; nCR meets all EBMT criteria for CR but has positive IF. Under EBMT criteria nCR is in the PR category n (%) 20 (6) 2 (<1) 8 (6) 2 (2) 12 (6) 0 (0) PR n(%) 101 (32) 54 (17) 49 (38) 27 (25) 52 (28) 27 (13) nCR , In two patients, the IF was unknown n(%) 21 (7) 3 (<1) 8 (6) 2 (2) 13 (7) 1 (<1) CR + PR n (%) 121 (38) 56 (18) 57 (45) 29 (26) 64 (34) 27 (13) p-value p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors <0.0001 0.0035 <0.0001 TTP was statistically significantly longer on the Bortezomib for Injection arm (see ). As shown in Bortezomib for Injection had a significant survival advantage relative to dexamethasone (p <0.05). The median follow-up was 8.3 months. For the 121 patients achieving a response (CR or PR) on the Bortezomib for Injection arm, the median duration was 8.0 months (95% CI: 6.9, 11.5 months) compared to 5.6 months (95% CI: 4.8, 9.2 months) for the 56 responders on the dexamethasone arm. The response rate was significantly higher on the Bortezomib for Injection arm regardless of beta 2 -microglobulin levels at baseline. Randomized, Open-Label Clinical Study of Bortezomib for Injection Subcutaneous vs Intravenous in Relapsed Multiple Myeloma An open-label, randomized, Phase 3 noninferiority study (NCT00722566) compared the efficacy and safety of the subcutaneous administration of Bortezomib for Injection vs the intravenous administration. This study included 222 bortezomib naïve patients with relapsed multiple myeloma, who were randomized in a 2:1 ratio to receive 1.3 mg/m 2 of Bortezomib for Injection by either the subcutaneous (n=148) or intravenous (n=74) route for eight cycles. Patients who did not obtain an optimal response (less than Complete Response (CR)) to therapy with Bortezomib for Injection alone after four cycles were allowed to receive oral dexamethasone 20 mg daily on the day of and after Bortezomib for Injection administration (82 patients in subcutaneous treatment group and 39 patients in the intravenous treatment group). Patients with baseline Grade ≥2 peripheral neuropathy or neuropathic pain, or platelet counts <50,000/µL were excluded. A total of 218 patients were evaluable for response. Stratification factors were based on the number of lines of prior therapy the patient had received (one previous line vs more than one line of therapy), and international staging system (ISS) stage (incorporating beta 2 -microglobulin and albumin levels; Stages I, II, or III). The baseline demographic and other characteristics of the two treatment groups are summarized as follows: the median age of the patient population was approximately 64 years of age (range: 38 to 88 years), primarily male (subcutaneous: 50%, intravenous: 64%); the primary type of myeloma is IgG (subcutaneous: 65% IgG, 26% IgA, 8% light chain; intravenous: 72% IgG, 19% IgA, 8% light chain), ISS staging I/II/III (%) was 27, 41, 32 for both subcutaneous and intravenous, Karnofsky performance status score was ≤70% in 22% of subcutaneous and 16% of intravenous, creatinine clearance was 67.5 mL/min in subcutaneous and 73 mL/min in intravenous, the median years from diagnosis was 2.68 and 2.93 in subcutaneous and intravenous respectively and the proportion of patients with more than one prior line of therapy was 38% in subcutaneous and 35% in intravenous. This study met its primary (noninferiority) objective that single agent subcutaneous Bortezomib for Injection retains at least 60% of the overall response rate after four cycles relative to single agent intravenous Bortezomib for Injection. The results are provided in Table 17 . Table 17: Summary of Efficacy Analyses in the Relapsed Multiple Myeloma Study of Bortezomib for Injection Subcutaneous vs Intravenous Subcutaneous Bortezomib for Injection Intravenous Bortezomib for Injection Intent to Treat Population (n=148) (n=74) Primary Endpoint Response Rate at 4 Cycles ORR (CR + PR) n (%) 63 (43) 31 (42) Ratio of Response Rates (95% CI) 1.01 (0.73, 1.40) CR n (%) 11 (7) 6 (8) PR n (%) 52 (35) 25 (34) nCR n (%) 9 (6) 4 (5) Secondary Endpoints Response Rate at 8 Cycles ORR (CR + PR) 78 (53) 38 (51) CR n (%) 17 (11) 9 (12) PR n (%) 61 (41) 29 (39) nCR n (%) 14 (9) 7 (9) Median Time to Progression, months 10.4 9.4 Median Progression-Free Survival, months 10.2 8.0 1 Year Overall Survival (%) Median duration of follow-up is 11.8 months 72.6 76.7 A Randomized, Phase 2 Dose-Response Study in Relapsed Multiple Myeloma An open-label, multicenter study randomized 54 patients with multiple myeloma who had progressed or relapsed on or after front-line therapy to receive Bortezomib for Injection 1 mg/m 2 or 1.3 mg/m 2 intravenous bolus twice weekly for two weeks on Days 1, 4, 8, and 11 followed by a ten day rest period (Days 12 to 21). The median duration of time between diagnosis of multiple myeloma and first dose of Bortezomib for Injection on this trial was two years, and patients had received a median of one prior line of treatment (median of three prior therapies). A single complete response was seen at each dose. The overall response rates (CR + PR) were 30% (8/27) at 1 mg/m 2 and 38% (10/26) at 1.3 mg/m 2 . A Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma Patients from the two Phase 2 studies, who in the investigators’ opinion would experience additional clinical benefit, continued to receive Bortezomib for Injection beyond 8 cycles on an extension study. Sixty-three (63) patients from the Phase 2 multiple myeloma studies were enrolled and received a median of seven additional cycles of Bortezomib for Injection therapy for a total median of 14 cycles (range: 7 to 32). The overall median dosing intensity was the same in both the parent protocol and extension study. Sixty-seven percent (67%) of patients initiated the extension study at the same or higher dose intensity at which they completed the parent protocol, and 89% of patients maintained the standard three week dosing schedule during the extension study. No new cumulative or new long-term toxicities were observed with prolonged Bortezomib for Injection treatment [see Adverse Reactions (6.1 )] . A Single-Arm Trial of Retreatment in Relapsed Multiple Myeloma A single-arm, open-label trial (NCT00431769) was conducted to determine the efficacy and safety of retreatment with Bortezomib for Injection. One hundred and thirty patients (≥18 years of age) with multiple myeloma who previously had at least partial response on a Bortezomib for Injection-containing regimen (median of two prior lines of therapy [range: 1 to 7]) were retreated upon progression with Bortezomib for Injection administered intravenously. Patients were excluded from trial participation if they had peripheral neuropathy or neuropathic pain of Grade ≥2. At least six months after prior Bortezomib for Injection therapy, Bortezomib for Injection was restarted at the last tolerated dose of 1.3 mg/m 2 (n=93) or ≤1 mg/m 2 (n=37) and given on Days 1, 4, 8 and 11 every three weeks for maximum of eight cycles either as single agent or in combination with dexamethasone in accordance with the standard of care. Dexamethasone was administered in combination with Bortezomib for Injection to 83 patients in Cycle 1 with an additional 11 patients receiving dexamethasone during the course of Bortezomib for Injection retreatment cycles. The primary endpoint was best confirmed response to retreatment as assessed by European Group for Blood and Marrow Transplantation (EBMT) criteria. Fifty of the 130 patients achieved a best confirmed response of Partial Response or better for an overall response rate of 38.5% (95% CI: 30.1, 47.4). One patient achieved a Complete Response and 49 achieved Partial Response. In the 50 responding patients, the median duration of response was 6.5 months and the range was 0.6 to 19.3 months. Figure 1: Time to Progression Bortezomib for Injection, Melphalan and Prednisone vs Melphalan and Prednisone Figure 2: Overall Survival Bortezomib for Injection, Melphalan and Prednisone vs Melphalan and Prednisone Figure 3: Time to Progression Bortezomib vs Dexamethasone (Relapsed Multiple Myeloma Study) Figure 4: Overall Survival Bortezomib vs Dexamethasone (Relapsed Multiple Myeloma Study) A Randomized, Open-Label Clinical Study in Patients with Previously Untreated Mantle Cell Lymphoma A randomized, open-label, Phase 3 study (NCT00722137) was conducted in 487 adult patients with previously untreated mantle cell lymphoma (Stage II, III or IV) who were ineligible or not considered for bone marrow transplantation to determine whether Bortezomib for Injection administered in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) resulted in improvement in progression-free survival (PFS) when compared to the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This clinical study utilized independent pathology confirmation and independent radiologic response assessment. Patients in the VcR-CAP treatment arm received Bortezomib for Injection (1.3 mg/m 2 ) administered intravenously on Days 1, 4, 8, and 11 (rest period Days 12 to 21); rituximab (375 mg/m 2 ) on Day 1; cyclophosphamide (750 mg/m 2 ) on Day 1; doxorubicin (50 mg/m 2 ) on Day 1; and prednisone (100 mg/m 2 ) on Day 1 through Day 5 of the 21 day treatment cycle. For patients with a response first documented at Cycle 6, two additional treatment cycles were allowed. Median patient age was 66 years, 74% were male, 66% were Caucasian and 32% were Asian. Sixty-nine percent of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of three (high‑intermediate) or higher and 76% had Stage IV disease. The majority of the patients in both groups received six or more cycles of treatment, 84% in the VcR-CAP group and 83% in the R-CHOP group. Median number of cycles received by patients in both treatment arms was six with 17% of patients in the R-CHOP group and 14% of subjects in the VcR-CAP group receiving up to two additional cycles. The efficacy results for PFS, CR and ORR with a median follow-up of 40 months are presented in Table 18. The response criteria used to assess efficacy were based on the International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphoma (IWRC). Final overall survival results at a median follow-up of 78.5 months are also presented in Table 18 and Figure 6. The combination of VcR-CAP resulted in statistically significant prolongation of PFS compared with R-CHOP ( see Table 18 , ). Table 18: Summary of Efficacy Analyses in the Previously Untreated Mantle Cell Lymphoma Study Efficacy Endpoint n: Intent to Treat patients VcR-CAP (n=243) R-CHOP (n=244) Progression-free Survival (by independent radiographic assessment) Events n (%) 133 (55) 165 (68) Median Based on Kaplan-Meier product limit estimates. (months) (95% CI) 25 (20, 32) 14 (12, 17) Hazard ratio Hazard ratio estimate is based on a Cox’s model stratified by IPI risk and stage of disease. A hazard ratio <1 indicates an advantage for VcR-CAP. (95% CI) 0.63 (0.50, 0.79) p-value Based on Log rank test stratified with IPI risk and stage of disease. <0.001 Complete Response Rate (CR) Includes CR by independent radiographic assessment, bone marrow, and LDH using ITT population. n (%) (95% CI) 108 (44) (38, 51) 82 (34) (28, 40) Overall Response Rate (CR + CRu + PR) Includes CR+ CRu+PR by independent radiographic assessment, regardless of the verification by bone marrow and LDH, using ITT population. n (%) 214 (88) 208 (85) (95% CI) (83, 92) (80, 89) Overall Survival Events n (%) 103 (42) 138 (57) Median (months) (95% CI) 91 (71, NE) 56 (47, 69) Hazard Ratio (95% CI) 0.66 (0.51, 0.85) Note: All results are based on the analysis performed at a median follow-up duration of 40 months except for the overall survival analysis, which was performed at a median follow-up of 78.5 months. CI = Confidence Interval; IPI = International Prognostic Index; LDH = Lactate dehydrogenase Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP = Bortezomib for Injection, rituximab, cyclophosphamide, doxorubicin, and prednisone. Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP = Bortezomib for Injection, rituximab, cyclophosphamide, doxorubicin, and prednisone. A Phase 2 Single-Arm Clinical Study in Relapsed Mantle Cell Lymphoma after Prior Therapy The safety and efficacy of Bortezomib for Injection in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study (NCT00063713) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and 92% were Caucasian. Of the total, 75% had one or more extra-nodal sites of disease, and 77% were Stage 4. In 91% of the patients, prior therapy included all of the following: an anthracycline or mitoxantrone, cyclophosphamide, and rituximab. A total of thirty-seven percent (37%) of patients were refractory to their last prior therapy. An intravenous bolus injection of Bortezomib for Injection 1.3 mg/m 2 /dose was administered twice weekly for two weeks on Days 1, 4, 8, and 11 followed by a ten day rest period (Days 12 to 21) for a maximum of 17 treatment cycles. Patients achieving a CR or CRu were treated for four cycles beyond first evidence of CR or CRu. The study employed dose modifications for toxicity [see Dosage and Administration (2.6 , 2.7 )] . Responses to Bortezomib for Injection are shown in Table 19 . Response rates to Bortezomib for Injection were determined according to the International Workshop Response Criteria (IWRC) based on independent radiologic review of CT scans. The median number of cycles administered across all patients was four; in responding patients the median number of cycles was eight. The median time to response was 40 days (range: 31 to 204 days). The median duration of follow-up was more than 13 months. Table 19: Response Outcomes in a Phase 2 Relapsed Mantle Cell Lymphoma Study Response Analyses (N=155) N (%) 95% CI   Overall Response Rate (IWRC) (CR + CRu + PR) 48 (31) (24, 39)     Complete Response (CR + CRu) 12 (8) (4, 13)        CR 10 (6) (3, 12)        CRu 2 (1) (0, 5)   Partial Response (PR) 36 (23) (17, 31) Duration of Response Median 95% CI   CR + CRu + PR (N=48) 9.3 months (5.4, 13.8)   CR + CRu (N=12) 15.4 months (13.4, 15.4)   PR (N=36) 6.1 months (4.2, 9.3) Figure 5: Progression Free Survival VcR-CAP vs R-CHOP (previously Untreated Mantle Cell Lymphoma Study) Figure 6: Overall Survival VcR-CAP vs R-CHOP (previously Untreated Mantle Cell Lymphoma Study)

NDC 10019-991-01 Bortezomib for Injection 3.5 mg/vial FOR INTRAVENOUS OR SUBCUTANEOUS USE Single Dose Vial Discard Unused Portion CONTENTS: Lyophilized vial contains 3.5 mg bortezomib and 35 mg mannitol. USUAL DOSE: See accompanying Package Insert for dosage information. Rx ONLY STORAGE: Store at 25ºC (77ºF); excursions permitted from 15º to 30ºC (59º to 86ºF) [See USP Controlled Room Temperature]. Protect from light (see Package Insert). For bar code position only LOT: EXP: Baxter Logo Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015, USA Made in Germany USA HA-65-01-792 C 22 barcode Vial Intravenous Use Label Bortezomib for Injection INTRAVENOUS INJECTION ONLY 0.9% NaCI symbol ADD 3.5 mL 0.9% Sodium Chloride To make 1 mg / mL final concentration Place sticker on vial Intravenous Bortezomib Place sticker on syringe Intravenous Bortezomib See Package Insert (Section 2) for full Instructions USA HA-65-01-801 C150 Bortezomib for Injection SUBCUTANEOUS INJECTION ONLY 0.9% NaCI Add 1.4 mL 0.9% Sodium Chloride To make 2.5 mg / mL final concentration Place sticker on vial Subcutaneous Bortezomib Place sticker on syringe Subcutaneous Bortezomib See Package Insert (Section 2) for full Instructions USA HA-65-01-800 C148 GTIN: SN: LOT: EXP: Bortezomib for Injection Barcode NDC 10019-991-01 See Reconstitution Information on Back Bortezomib for Injection 3.5 mg/vial FOR INTRAVENOUS OR SUBCUTANEOUS USE Single Dose Vial – Discard Unused Portion Baxter Logo HA-80-03-191 USA CONTENTS: Lyophilized vial contains 3.5 mg bortezomib and 35 mg mannitol. RECONSTITUTION: See back of this carton or Package Insert, Section 2. USUAL DOSE: See accompanying Package Insert for dosage information. Rx ONLY STORAGE: Store at 25° C (77° F); excursions permitted from 15° to 30° C (59° to 86° F) [See USP Controlled Room Temperature]. Protect from light (see Package Insert). C 501 NDC 10019-991-01 Bortezomib for Injection 3.5 mg/vial Reconstitution Information SUBCUTANEOUS INJECTION ONLY 0.9% NaCI Add 1.4 mL 0.9% Sodium Chloride To make 2.5 mg / mL final concentration INTRAVENOUS INJECTION ONLY 0.9% NaCI Add 3.5 mL 0.9% Sodium Chloride To make 1 mg / mL final concentration 2347B0016 Barcode (01) 20310019991010 Baxter is a registered trademark of Baxter International Inc. Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015, USA Made in Germany Reconstitution Information SUBCUTANEOUS INJECTION ONLY 0.9% NaCI Add 1.4 mL 0.9% Sodium Chloride To make 2.5 mg / mL final concentration INTRAVENOUS INJECTION ONLY 0.9% NaCI Add 3.5 mL 0.9% Sodium Chloride To make 1 mg / mL final concentration Bortezomib Representative Container Label 10019-991-01 Representative Bortezomib Intravenous Label 10019-991-01 Representative Bortezomib Subcutaneous Label 10019-991-01 Bortezomib Representative Carton Label 10019-991-01 1 of 2 Bortezomib Representative Carton Label 10019-991-01 2 of 2